Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px
Document › Details

Merck KGaA. (7/14/14). "Press Release: Merck Serono Appoints Luciano Rossetti as Global Head of R&D". Darmstadt.

Organisations Organisation Merck Serono (division of Merck KGaA)
  Group Merck (DE) (Group)
  Organisation 2 Merck, Sharp & Dohme
  Group Merck (US) (MSD) (Group)
Products Product drug development
  Product 2 drug discovery
Persons Person Rossetti, Luciano (Merck (DE) 201407– Global Head RnD at Merck Serono before Merk Sharp & Dohme)
  Person 2 Garijo, Belén (Merck (DE) 201310– CEO of Merck Serono before COO sinc 2011 before Sanofi)
     


Merck Serono, the biopharmaceutical division of Merck, today announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014.

In his most recent role Rossetti (57) acted as Senior Vice President Late Stage Development at Merck Sharp & Dohme, or MSD. In this position, he was responsible for the entire clinical development from Phase II to Phase V across all therapeutic areas. At MSD, he played a key role in shaping and implementing the development strategy of several potential breakthrough compounds such as Anti PD-1. He also restructured the clinical genetics group to better leverage the collaboration between discovery and clinical development. Before joining MSD in 2006, Rossetti was an internationally recognized academic scientist for 18 years.

"I'm thrilled to welcome Luciano Rossetti to Merck," said Belén Garijo, President and CEO at Merck Serono. "His breadth of experience and solid track record in both research as well as development together with his distinct leadership profile will be instrumental in driving the development of our promising pipeline to ensure that we will meet our strategic milestones and deliver innovative solutions for unmet medical needs to patients around the world."

Rossetti will be based in Billerica, outside Boston, Massachusetts (U.S.), and share his time between Merck's headquarters in Darmstadt (Germany) and Billerica - one of Merck Serono's four global R&D hubs.


All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website www.merckgroup.com/media. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 38,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px

More documents for Merck (DE) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top